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Abstract This study investigated the role of two fatty
acid ethanolamides, the endogenous cannabinoid ananda-
mide and its structural analog oleoylethanolamide in sleep
deprivation of human volunteers. Serum and cerebrospinal
ﬂuid (CSF) samples were obtained from 20 healthy vol-
unteers before and after a night of sleep deprivation with an
interval of about 12 months. We found increased levels of
oleoylethanolamide in CSF (P = 0.011) but not in serum
(P = 0.068) after 24 h of sleep deprivation. Oleoylethan-
olamide is an endogenous lipid messenger that is released
after neural injury and activates peroxisome proliferator-
activated receptor-a (PPAR-a) with nanomolar potency.
Exogenous PPAR-a agonists, such as hypolipidemic ﬁ-
brates and oleoylethanolamide, exert both neuroprotective
and neurotrophic effects. Thus, our results suggest that
oleoylethanolamide release may represent an endogenous
neuroprotective signal during sleep deprivation.
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Introduction
Oleoylethanolamide is a fatty acid ethanolamide (FAE) and
a natural analog of the endogenous cannabinoid ananda-
mide. There is no detailed research on the role of
endocannabinoids in sleep in humans. Anandamide is
known to engross slow-wave sleep by increasing adenosin
levels in the forebrain of rodents (Murillo-Rodriguez et al.
2003). This is blocked by the cannabinoid CB1-receptor
antagonist rimonabant. Oleamide is an endogenous sleep-
inducing lipid with putative cannabinomimetic properties
(Lees and Dougalis 2004). Murillo-Rodriguez et al. (2007)
supposed oleoylethanolamide, which—unlike oleamide—
activates the nuclear peroxisome proliferator-activated
receptor-a (PPAR-a) to increase alertness and to participate
in the regulation of waking.
Up to now, elevated levels of oleoylethanolamide and
anandamide were found in human microdialysates within
the ﬁrst day of ischemia as well as following neural injury
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DOI 10.1007/s00702-008-0169-6or other stressors associated with necrosis. Furthermore,
massive increases in FAEs and their precursor phospho-
lipids have been found during the acute phase of stroke in
the adult rat brain (for review, see Pacher et al. 2006).
Thereby it was suggested that increases of brain FAE levels
serve a neuroprotective function mediated by CB1-recep-
tors. Oleoylethanolamide does not bind to cannabinoid CB-
receptors but to PPAR-a, thereby activating a different
neuroprotective mechanism.
Sleep deprivation has been hypothesized to represent an
oxidative challenge for the brain and that sleep may have a
protective role against oxidative damage. While Gopala-
krishnan et al. (2004) found no change in antioxidant
enzymatic activities or increased oxidant production in the
brain or in peripheral tissues after prolonged sleep depri-
vation, other studies suppose that sleep deprivation may
result in a condition of oxidative stress including a reduc-
tion in glutathione levels in whole brains of rats
(D’Almeida et al. 1998). Ramanathan et al. (2002) showed
that prolonged sleep deprivation results in signiﬁcant
decreases in the activity of superperoxide-dismutase in rat
hippocampus and brainstem. This effect may be due to the
degradation of antioxidative enzymes after prolonged
activation during wakefulness, which suggests an alteration
in the metabolism resulting in oxidative stress. Even if
sleep deprivation might not show extensive effects com-
parable to cerebral injury or tissue necrosis, FAEs have
been shown previously to be elevated during situations of
cellular stress and oxidative stress factors are elevated
following sleep deprivation (Pacher et al. 2006). Therefore,
in this study, we investigated whether the levels of the
endogenous PPAR-a agonist oleoylethanolamide and the
endocannabinoid anandamide were elevated in CSF and
serum of healthy individuals after acute sleep deprivation.
Methods
The Ethics Committee of the Medical Faculty of the Uni-
versity of Cologne reviewed and approved the protocol of
this study and the procedures for sample collection and
analysis. All volunteers gave written informed consent
twice at least 1 day prior to each lumbar puncture after
extensive introduction into the procedures and goal of this
study. The healthy subjects received an allowance for the
participation in this trial. All investigations were conducted
in accordance with the Declaration of Helsinki.
This study was integral to a larger project on endocan-
nabinoid levels in CSF and serum of healthy volunteers and
patients suffering psychiatric disorders. As part of that,
volunteers were investigated to establish baseline levels of
endocannabinoids in a healthy control population (Giuff-
rida et al. 2004). Twenty healthy volunteers (eight males
and twelve females; median age 26 years, range 19–
49 years.) with no family history and no clinical indication
for any relevant medical, psychiatric or neurological dis-
turbances were included in our study to investigate effects
of sleep withdrawal on endocannabinoid levels. Necessary
criteria for inclusion were absence of cannabis use within
the last year and lifetime cannabis use not exceeding ﬁve
times. No positive urine drug screening for illicit drugs was
accepted at time of the lumbar puncture (LP). Living cir-
cumstances (e.g. job status, social environment) for those
volunteers selected did not change substantially during this
period.
Subjects were lumbar-punctured twice during the course
of our study using a nontraumatic LP procedure. The ﬁrst
LP was done under regular sleep condition. The second LP
took place after 24 h of sleep deprivation about 1 year later
to avoid seasonal inﬂuences and artiﬁcial alterations in
cerebrospinal ﬂuid (CSF) due to a previous LP in the near
past. All subjects spent the nights before both LPs at home;
sleep quality before the ﬁrst lumbar puncture was assessed
by the self-rating questionnaire for fatigue and for sleep
and awakening quality (SSS). The night of sleep depriva-
tion was spent in the habitual environment of the
volunteers.
Alertness was monitored by wrist actigraphy, using the
‘‘Actiwatch2000,’’ a piezoelectric transductor recording a
maximum of 240 wrist motions per minute. Actiwatch
was given to the volunteers 24 h before the second
lumbar puncture. Volunteers showing a mosaic of inac-
tivation at the actiwatch-scan of more than 5 min during
the 24-h period were excluded from the experiment. This
approach allowed us to continuously monitor the subjects
during the night of sleep withdrawal (Benson et al.
2004).
Sleep habits in volunteers were assessed for 7 days
before sleep deprivation using a sleep protocol to exclude
interferences of the sleep rhythm. For sleep deprivation,
volunteers were requested to stay awake for one night
without consuming any coffee or alcohol during that night;
intake of food was allowed. All LPs were done between
10:00 and 12:00 AM, and each time peripheral blood was
collected. All samples revealed no pathognomonic cell
counts, CSF/serum albumin ratios or oligoclonal bands.
Virological and microbiological testing of the CSF was
negative in all cases.
In all subjects, we measured CSF and serum levels of
oleoylethanolamide along with anandamide. To quantify
FAEs, CSF aliquots (1 ml) and serum were spiked with
25 pmol of [
2H4]-anandamide and [
2H4]-oleoylethanola-
mide (internal standards) and prepared for further analysis
as described previously (Schreiber et al. 2007). Fatty acid
ethanolamides were puriﬁed and quantiﬁed by isotope
dilution high performance liquid chromatography/mass
302 D. Koethe et al.
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MS system equipped with a octadecylsilica (ODS) Hypersil
column (100 9 4.6 mm
2, i.d. 5 lm) (Agilent Technolo-
gies). MS analyses were performed with an electro-spray
ion source as previously described (for details, see Giuff-
rida et al. 2004).
Statistical analyses were performed using SPSS and R
software (library: exactRankTests). Because of apparent
non-normality of empirical data distributions, location
differences in (paired) measurements were assessed by
Wilcoxon signed rank or rank sum test (exact).
Results
The measurements of oleoylethanolamide and anandamide
levels in CSF of 20 healthy volunteers before and after 24 h
sleep deprivation are illustrated in Fig. 1. Oleoylethanola-
mide levels in CSF (median 0.62, interquartile range
0.34–2.60 pmol/ml) increased signiﬁcantly after 24 h of
sleep deprivation [7.44, 1.18–20.14 pmol/ml; P = 0.011
(P = 0.044, Bonferroni-adjusted)]. In serum, the increase
from 7.70, 6.13–15.00 pmol/ml to 12.34, 6.80–21.21 pmol/
ml was borderline signiﬁcant (P = 0.068). Anandamide
levels were neither affected in CSF nor in serum
(P = 0.887 and P = 0.229, respectively). Notably, the
oleoylethanolamide level increase in CSF was more pro-
nounced in women (19.52, 0.68–23.39 pmol/ml) than in
men (0.84, 0.47–5.84 pmol/ml, P = 0.211). There were no
signiﬁcant effects observed on age or gender on study
variables. We found no difference between the self-reported
hours of sleep 7 days before ﬁrst and second LP
(7.2 ± 1.3 h vs. 7.5 ± 1.4 h). No mean metabolomic
markers were changed between the ﬁrst and second LP (as
e.g. in clinical chemistry, sex hormones or BMI). Cortisol
levels were measured as a stress marker in both conditions
and revealed no change between ﬁrst and second lumbar
puncture (156.2 ± 70.2 nmol/l vs. 167.4 ± 90.1 nmol/l;
P = 0.691). For serum glucose, no differences were found
between regular and sleep withdrawal conditions
(87.40 ± 14.3 vs. 87.16 ± 16.8 mg/dl; P = 0.71).
Discussion
Our results show a signiﬁcant increase of oleoylethanola-
mide in human CSF after 24 h of sleep deprivation,
whereas the levels of the endocannabinoid anandamide
remain unaffected. Interestingly, there is no indication for a
functional role of anandamide in sleep induction in humans
as hypothesized previously (Mechoulam et al. 1997). In
rats, Murillo-Rodriguez et al. (2006) showed that ananda-
mide increases slow wave sleep, which can be blocked by
administration of the cannabinoid CB1-receptor antagonist
rimonabant, indicating that the endocannabinoid system is
involved in sleep regulation (Murillo-Rodriguez et al.
2001).
Further, recent data in rats indicate diurnal variations of
anandamide and oleoylethanolamide in CSF with maxi-
mum values for oleoylethanolamide during the late light
phase, decreasing in the dark phase (Murillo-Rodriguez
et al. 2006). This research was done in rats, which are
awake in the lights-off period. Translating these results to
the human sleep/wake cycle it may be hypothesized that
the concentration of oleoylethanolamide in CSF (in con-
trast to brain tissue) may decrease during daytime and
increase during sleep. Given these assumptions, the
increase of oleoylethanolamide is not very likely the result
of an accumulation, particularly with regard to the very
limited extracellular life span of endocannabinoids
(Piomelli 2003). As in our study the second lumbar punc-
ture was done at the same time of the day as the ﬁrst one;
circadian rhythms should not confound our results. Oleo-
ylethanolamide is renowned for modulation of feeding,
body weight and lipid metabolism, as its levels decrease
during food deprivation and increase upon feeding (Fu
et al. 2007). This should not be a confounder as well, as
oleoylethanolamide plays its role as a local satiety
hormone in the intestine (Lo Verme et al. 2005), and the
feeding conditions were not changed before and after
sleep-withdrawal in this study.
Like anandamide, oleoylethanolamide is synthesized
by neurons and other cells in a stimulus-dependent
manner and is rapidly eliminated by enzymatic hydrolysis
Fig. 1 Box–whiskers-plots (box shows 25th, 50th and 75th percentile
of empirical distribution; whiskers extend to smallest and largest
value excluding outliers) of acid ethanolamides, oleoylethanolamide
and anandamide, in human cerebrospinal ﬂuid (CSF) and in serum
before and after a single night of controlled sleep withdrawal in
healthy volunteers (circles: women, triangles: men). The P value
(two-sided) is from exact Wilcoxon signed rank test
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123(for review, see Pacher et al. 2006). Oleoylethanolamide
binds with high afﬁnity to the PPAR-a, a nuclear receptor
that is known to regulate several aspects of lipid metabo-
lism and induces satiety by activating PPAR-a (Fu et al.
2003). PPAR-a is also involved in neuroprotection through
activation of antioxidant and anti-inﬂammatory mecha-
nisms. It has been shown that pretreatment with the
synthetic PPAR-a agonist fenoﬁbrate is neuroprotective
against cerebral injury (e.g., Deplanque et al. 2003). Fur-
thermore, treatment with PPAR-a agonists as well as
monounsaturated and polyunsaturated fatty acids (PUFA)
induces an increase in activity of major antioxidant
enzymes in the brain (Deplanque et al. 2003).
The distribution of PPAR-a receptors in the human brain
remains mainly conjectural. Moreno et al. (2004) have
provided an overview on the distribution of PPARs in the
adult rat central nervous system (CNS). They reported the
highest densities of PPAR-a in the hippocampal dentate
gyrus and the granular cell layer of the cerebellar cortex.
Furthermore, they observed PPAR expression in previously
unreported locations, such as the basal ganglia, the reticular
formation, some thalamic, mesencephalic and cranial
motor nuclei and the large motor neurons of the spinal cord
(Moreno et al. 2004). This widespread distribution in the
CNS also includes brain areas involved in sleep regulation
such as the thalamus and the reticular formation.
It has been hypothesized that sleep may serve an anti-
oxidant function by removing free radicals or oxygen
reactive species produced during waking time and that
restoration of antioxidant balance is a property of recovery
sleep (Everson et al. 2005). However, these protective
mechanisms, especially in the brain, are still poorly
understood. Interestingly, several studies have found that
sleep deprivation is a stressful condition, which is associ-
ated with the disruption of various physiological processes
(McEwen 2006). Reduced glutathione levels have been
found in different brain regions, such as thalamus and
hypothalamus, as well as in different organs of sleep-
deprived animals (D’Almeida et al. 1998; Everson et al.
2005). Additionally, markers of generalized cell injury
accompanied these decreases (Everson et al. 2005) and
decreased superoxide-dismutase activity has been shown in
hippocampus and brainstem after prolonged sleep depri-
vation (Ramanathan et al. 2002). The activation of these
components of the antioxidant defense system suggests that
sleep deprivation is a stressful condition for the entire body
and for the brain in particular.
Several studies have shown that PPAR-a activation
enhances antioxidative enzyme activities (Deplanque et al.
2003). Activation of PPAR-a in vivo causes an upregula-
tion of the mRNA and protein levels of a number of
peroxisome- and nonperoxisome-associated enzymes and
structural proteins, including the antioxidant enzymes
catalase, superperoxide-dismutase and mediators of the
glutathione pathway. In this context, pretreatment with
fenoﬁbrate reduces cerebral infarct volume in apolipopro-
tein E-deﬁcient mice. The neuroprotective effect of
fenoﬁbrate is completely absent in PPAR-a-deﬁcient mice,
suggesting that PPAR-a activation is involved as a
protective mechanism against cerebral injury (Deplanque
et al. 2003).
We failed to conﬁrm the initially hypothesized increase
of anandamide after sleep deprivation questioning its pro-
posed role in sleep induction in humans (Mechoulam et al.
1997). This is in line with ﬁndings on cannabinoid CB1-
receptor gene expression, which is suggested to be modu-
lated by sleep. While sleep rebound signiﬁcantly increased
CB1-receptor protein and decreased respective mRNA, no
effects were found following sleep deprivation (Martinez-
Vargas et al. 2003). Interestingly, according to the product
information, the CB1-receptor antagonist rimonabant
induces sleep disturbances frequently (range 1–10%) but
also sedation (range 0.1–1%) in clinical trials.
Several shortcomings might have inﬂuenced our some-
how preliminary data; ﬁrst, a randomized, balanced cross-
over design would have been the ideal design for the trial.
Second, EEG recordings might have provided more
detailed information on sleep quality instead of an actig-
raphy for control of sleep deprivation only.
Conclusions
Our results show that sleep deprivation signiﬁcantly ele-
vates the endogenous PPAR-a ligand oleoylethanolamide
in human CSF. These ﬁndings may suggest the hypothesis
that elevation of oleoylethanolamide may serve a potential
neuroprotective role during sleep deprivation via activation
of PPAR-a. Despite its limits, this pilot trial addresses for
the ﬁrst time the role of anandamide and oleoylethanola-
mide in sleep regulation in humans. However, various
questions remain unanswered: Which physiological stimuli
initiate and terminate oleoylethanolamide biosynthesis in
brain? Does oleoylethanolamide act on PPAR-a receptors
in the brain as it does in the periphery? Does activation of
PPAR-a elicit a neuroprotective response during sleep
deprivation? These questions need to be addressed by
further studies translationally targeting the role of oleoy-
lethanolamide during sleep deprivation.
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